LIFE Stock Overview
Public Joint-Stock Company ‘Pharmsynthez’, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Public Joint-Stock Company "Pharmsynthez" Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₽4.51 |
| 52 Week High | ₽7.00 |
| 52 Week Low | ₽2.65 |
| Beta | 0.19 |
| 1 Month Change | 0% |
| 3 Month Change | 10.15% |
| 1 Year Change | -23.51% |
| 3 Year Change | -0.77% |
| 5 Year Change | -62.92% |
| Change since IPO | -81.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| LIFE | RU Pharmaceuticals | RU Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | -0.4% |
| 1Y | -23.5% | 5.9% | 4.2% |
Return vs Industry: LIFE underperformed the Russian Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: LIFE exceeded the Russian Market which returned -38.2% over the past year.
Price Volatility
| LIFE volatility | |
|---|---|
| LIFE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in RU Market | 9.9% |
| 10% least volatile stocks in RU Market | 2.5% |
Stable Share Price: LIFE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LIFE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Petr Kurglyakov | www.pharmsynthez.com |
Public Joint-Stock Company ‘Pharmsynthez’, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez’ has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia.
Public Joint-Stock Company "Pharmsynthez" Fundamentals Summary
| LIFE fundamental statistics | |
|---|---|
| Market cap | ₽1.36b |
| Earnings (TTM) | -₽669.67m |
| Revenue (TTM) | ₽451.32m |
3.0x
P/S Ratio-2.0x
P/E RatioIs LIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIFE income statement (TTM) | |
|---|---|
| Revenue | ₽451.32m |
| Cost of Revenue | ₽244.37m |
| Gross Profit | ₽206.95m |
| Other Expenses | ₽876.62m |
| Earnings | -₽669.67m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.22 |
| Gross Margin | 45.85% |
| Net Profit Margin | -148.38% |
| Debt/Equity Ratio | 86.9% |
How did LIFE perform over the long term?
See historical performance and comparison